Kiniksa Pharmaceuticals International, plc $KNSA Shares Purchased by Acadian Asset Management LLC

Key Points

• Acadian Asset Management LLC significantly increased its stake in Kiniksa Pharmaceuticals International by 170.3% during the first quarter, owning over 1 million shares valued at approximately $22.9 million.
• Several other institutional investors have also enhanced their positions, with 53.95% of Kiniksa's stock now held by institutional investors.
• Wall Street analysts have raised their target prices for Kiniksa Pharmaceuticals, with Wells Fargo setting a new target of $42.00 and Jefferies Financial Group increasing theirs to $54.00, contributing to an overall "Buy" rating for the stock.

Acadian Asset Management LLC raised its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 170.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,034,321 shares of the company's stock after acquiring an additional 651,700 shares during the quarter. Acadian Asset Management LLC owned approximately 1.42% of Kiniksa Pharmaceuticals International worth $22,961,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock valued at $74,606,000 after acquiring an additional 151,604 shares during the last quarter. Millennium Management LLC grew its position in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after buying an additional 67,452 shares in the last quarter. Nuveen Asset Management LLC grew its position in shares of Kiniksa Pharmaceuticals International by 7.3% during the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after buying an additional 54,361 shares in the last quarter. Parkman Healthcare Partners LLC grew its position in shares of Kiniksa Pharmaceuticals International by 1.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company's stock worth $15,141,000 after buying an additional 10,209 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $16,992,000. Institutional investors own 53.95% of the company's stock.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 29,325 shares of the stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the sale, the insider owned 57,403 shares of the company's stock, valued at $1,868,467.65. This trade represents a 33.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ross Moat sold 3,523 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $35.31, for a total value of $124,397.13. Following the completion of the sale, the insider directly owned 9,415 shares in the company, valued at $332,443.65. This represents a 27.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 544,971 shares of company stock worth $18,227,065 over the last quarter. Corporate insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock traded down $0.68 during trading on Tuesday, hitting $35.88. 90,276 shares of the company traded hands, compared to its average volume of 661,635. The stock's 50-day simple moving average is $32.03 and its 200 day simple moving average is $27.30. The company has a market cap of $2.66 billion, a PE ratio of 897.22 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $37.34.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KNSA. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Jefferies Financial Group raised their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 7th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.